Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting monoclonal antibody. An investigator-led, industry supported, multicentre, open-label, single treatment arm, prospective clinical tr
Read time: 1 mins
Last updated:31st Dec 2010
The main purpose of this study is to investigate whether rituximab, a new monoclonal antibody used in the treatment of severe rheumatoid arthritis, protects bone. To this end we will measure markers of bone turnover in blood and measure bone density of the spine, forearms and hips with a so-called DEXA scanner before and one year after the first infusion of rituximab.
|Study start date||2010-12-31|